Kapil Dhingra is the managing member of KAPital Consulting, LLC, a company he founded in 2008 that is dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize clinical and commercial advances in oncology. He is currently a member of the Board of Directors of LAVA Therapeutics B.V., Black Diamond Therapeutics, Inc., Median Technologies Inc., and Autolus Therapeutics plc. He has previously served on the Boards of several successful biotech companies, including Exosome Diagnostics, Five Prime Therapeutics Inc., Advanced Accelerator Applications S.A., Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics which were all acquired by major pharmaceutical companies.
From 1999 to 2008 Kapil Dhingra served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine from 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008.
Kapil is board-certified in Internal Medicine and Medical Oncology. He serves as a member of the NCI Experimental Therapeutics panel, as well as the New Drug Advisory Committee of the EORTC.
How do I contact Kapil Dhingra?
Has Kapil Dhingra been buying or selling shares of Replimune Group?
Kapil Dhingra has not been actively trading shares of Replimune Group during the past quarter. Most recently, Kapil Dhingra sold 3,169 shares of the business's stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a transaction totalling $32,957.60. Learn More on Kapil Dhingra's trading history.
Who are Replimune Group's active insiders?
Are insiders buying or selling shares of Replimune Group?
During the last year, insiders at the sold shares 11 times. They sold a total of 109,686 shares worth more than $910,418.89. The most recent insider tranaction occured on December, 9th when Director Kapil Dhingra sold 3,169 shares worth more than $32,957.60. Insiders at Replimune Group own 5.2% of the company.
Learn More about insider trades at Replimune Group. Information on this page was last updated on 12/9/2025.
